Replies to post #223659 on Biotech Values

[Bickema]

Ocaliva (OCA) is an FXR agonist. I’ve posted on numerous occasions that I don’t think Ocaliva has what it takes to garner big sales, due to its side-effect profile, and the top-line REGENERATE data are consistent with such a viewpoint

Good news for ENTA? Can they avoid the side effects you speak of?

[DewDiligence]

Summary of ICPT’s phase-3 data—including the sky-high pruritus rate:

http://www.evaluate.com/vantage/articles/news/trial-results/intercepts-nash-hopes-rest-ocalivas-borderline-hit

[DewDiligence]

ICPT closes +6% (after having been much higher in early trading).